<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672733</url>
  </required_header>
  <id_info>
    <org_study_id>pHeNIx study</org_study_id>
    <secondary_id>2019-A01803-54</secondary_id>
    <nct_id>NCT04672733</nct_id>
  </id_info>
  <brief_title>Hizentra® in Inflammatory Neuropathies - pHeNIx Study</brief_title>
  <acronym>pHeNIx</acronym>
  <official_title>Hizentra® in Inflammatory Neuropathies - pHeNIx Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pHeNIx study, a national multicentre prospective non-interventional study, should help to&#xD;
      describe the conditions of use for Hizentra® and the methods for switching from the IV to SC&#xD;
      route in everyday practice, together with the tolerability and efficacy of treatment, which&#xD;
      is monitored using a patient application (PRO: Patient-Reported Outcomes).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological and rare type of&#xD;
      autoimmune disorder. Intravenous immunoglobulin (IVIg) is the first-line treatment for CIDP&#xD;
      which has been proven to be effective. For several years, published cases have suggested that&#xD;
      the Sub-Cutaneous Ig (SCIg) may be an alternative treatment to IVIg in the treatment of CIDP.&#xD;
      Compared to IVIg treatment, the SCIg can achieve more stable plasma IgG concentrations,&#xD;
      suggesting a potential reduction in the dose exhaustion effect at the end of the cycle, but&#xD;
      also fewer systemic effects. SC administration also enables more straightforward treatment to&#xD;
      be given for ambulatory patients.&#xD;
&#xD;
      Based on the PATH study (NCT01545076), a double blind placebo-controlled, randomised,&#xD;
      prospective, international multicentre phase III study, Hizentra® obtained an extension of&#xD;
      its marketing authorization for the CIDP indication as maintenance treatment after&#xD;
      stabilisation with IVIg.&#xD;
&#xD;
      However, in the &quot;real-life&quot; situation, the literature is still based at present on small&#xD;
      series of patient or short-term follow-up periods.&#xD;
&#xD;
      However, the methods for switching from the IV to the SC route and the characteristics of&#xD;
      patients receiving this treatment are not known. In addition, SCIg administration remote from&#xD;
      a specialist centre without assistance from a health professional no longer enables a more&#xD;
      regular assessment of the patient in terms of tolerability and efficacy.&#xD;
&#xD;
      The pHeNIx study, a national multicentre prospective non-interventional study, should help to&#xD;
      describe the conditions of use for Hizentra® and the methods for switching from the IV to SC&#xD;
      route in everyday practice, together with the tolerability and efficacy of treatment, which&#xD;
      is monitored using a patient application (PRO: Patient-Reported Outcomes). The study duration&#xD;
      is estimated to be 36 months in view of: a 24-month inclusion period and a 12-month follow-up&#xD;
      period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Suspended due to the COVID situation&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Length of time of Continuation of treatment</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Non-continuation is defined by:&#xD;
an increase in the INCAT score of over one point measured in a consultation despite a bolus dose of IVIg and/or after increasing the dose of Hizentra®&#xD;
stopping treatment with Hizentra®</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time between the last dose of IVIg and starting Hizentra®</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total dose of the last course of IVIg</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The interval between courses of IVIg</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total dose of the first course of Hizentra</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days of the first course of Hizentra</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Self-administrations or administrations by a state-registered nurse</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The daily dose of Hizentra</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The daily volume of Hizentra</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the infusion</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusion sites</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients completing the Patient Reported Outcome (PRO) tests at home</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rasch-built Overall Disability Scale (RODS) incapacity scale score by patient</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-metre walking test score by patient</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rasch-built Overall Disability Scale (RODS) incapacity scale score by doctor</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-metre walking test score by doctor</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time since the diagnosis of CIDP</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol-5D (EQ-5D) quality of life score</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pictorial Representation of Illness and Self Measure (PRISM) score</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Inflammatory Demyelinating Polyneuropathy</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hizentra</intervention_name>
    <description>Solution for injection for subcutaneous use</description>
    <other_name>IgPro20</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        French cohort of patients with CIDP&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient (aged ≥18 years)&#xD;
&#xD;
          -  Patients suffering from CIDP according to EFNS/PNS 2010 criteria&#xD;
&#xD;
          -  Planned switch from IVIg to Hizentra®&#xD;
&#xD;
          -  Patient treated with at least 3 courses of IV immunoglobulin and deemed by the&#xD;
             investigator to be dependent on immunoglobulins&#xD;
&#xD;
          -  Patient deemed to be stable, with no change in their treatment for the disease during&#xD;
             the 3 months prior to inclusion&#xD;
&#xD;
          -  Patients who have a smart phone, a tablet or a computer&#xD;
&#xD;
          -  Patients who have been informed verbally and in writing of the purposes of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant participation in an interventional clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond poincaré, Garches</name>
      <address>
        <city>Garche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Wertheimer,HCL</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CIDP</keyword>
  <keyword>IgPro20</keyword>
  <keyword>Hizentra</keyword>
  <keyword>Subcutaneous Immunoglobulins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

